Evidence map›Paper›PMID 42144287›Full record

ArticleAmerican journal of hematology2026

Predictors of Relapse and Post-Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome-Negative B-ALL.

Sankalp Arora, Hagop Kantarjian, Koji Sasaki, Nitin Jain, Zhouxuan Li, Wei Qiao, Sanam Loghavi, Guilin Tang, Caitlin Rausch, Farhad Ravandi and 9 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Sankalp AroraDivision of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Hagop KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-1908-3307
Koji SasakiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Nitin JainDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Zhouxuan LiDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Wei QiaoDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Sanam LoghaviDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Guilin TangDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Caitlin RauschDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-4166-5717
Farhad RavandiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-7621-377X
Fadi G HaddadDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-9702-8485
Jayastu SenapatiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-6831-2567
Guillermo Montalban BravoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Alexandre BazinetDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0001-5538-4943
Rita KhouriDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Rebecca GarrisDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-3631-2482
Nicholas J ShortDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Elias JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0003-4465-6119

Funding

NCI NIH HHS CA1100632University of Texas MD Anderson Cancer Center CA016672
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42144287
PMCPMC13331635

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.